TREATMENT OF HYPERTENSIVE PATIENTS WITH HIGH OR VERY HIGH CARDIOVASCULAR RISK. PHARMACOECONOMIC EFFICIENCY OF A TRIPLE COMBINATION THERAPY CONTAINING ANGIOTENSIN CONVERTING ENZYME INHIBITOR, CALCIUM CHANNEL BLOCKER AND STATIN
https://doi.org/10.21518/2079-701X-2016-13-6-12
Abstract
Arterial hypertension (AH) is one of the most common cardiovascular diseases and a frequent cause of cardiovascular complications and early disability. In Russia, AH of varying severity may affect about 30% of the population. [1] Hypertension is the causal factor for 27% of cardiovascular events in women and 37% in men. [2] AH accounts for about 14% of myocardial infarctions in men and 30% in women [3], 35% of ischemic strokes, 39% of chronic heart failures in men and 59% in women, and 56% of cases of chronic renal disease. [4–6]
About the Author
I. N. DYAKOV
I. I. MECHNIKOV Research Institute of Vaccines and Sera, Remedium
Russian Federation
Russian Federation
References
1. Haroun MK, Jaar BG, Hoffman SC et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J. Am. Soc. nephrol., 2003, 14: 2934-2941.
2. Kesselheim А et al. JAMA, 2003, 300: 2514-2526.
3. Laguna-Goya N, Blazquez-Perez A, PozoHernandez C. Regulation about generics approval. Farm Hosp, 2006 novDec, 30(6): 379-384.
4. Ohira T, Shahar E, Chambless LE, Rosamond WD et al. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities Study. Stroke, 2006, 37: 2493-2498.
5. Rabbani A, Alexander GC. Out-ofpocket and total costs of fixed-dose combination antihypertensives and their components. Am. J. Hypertens., 2008, 21(5): 509-513.
6. Saleh SS, Szebenyi S, Carter JA, Zacher C, Belletti D. Patterns and associated health services costs of antihypertensive drug modifications. J. Clin. Hypertens. (Greenwich), 2008, 10(1): 43-50.
7. Олейникова Г.Л. Комбинированная терапия артериальной гипертонии. РМЖ, 2008, 21: 1470. / Oleinikova G.L. Combination therapy of hypertension. RMZ, 2008, 21: 1470.
8. Глезер М.Г. Отдадут ли первенство ß-адреноблокаторы в лечении артериальной гипертонии? Материалы образовательного мастер-курса по артериальной гипертонии и сердечно-сосудистому риску. Консилиум (экстравыпуск), 2007, 11. / Glezer M.G. Will ß-blockers yield precedence in the treatment of hypertension? Proceedings of the educational master course on hypertension and cardiovascular risk. Consilium (extra issue), 2007, 11.
9. Кондейевски Ж.М. Карманные рекомендации для врачей по ведению пациентов с гипертензией. Под ред. С.В. Недогода, А.О. Конради. М.: Ремедиум, 2015. / Kondeyevski D.M. Pocket guidelines for the management of patients with hypertension. Ed. by S.V. Nedogoda, S.A. Conradi. М.: Remedium, 2015.
10. Lewington S, Clarke R, Qizilbash N et al. Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 2002 Dec 14, 360(9349): 1903-13.
11. Roth GA, Forouzanfar MH, Moran AE et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med, 2015 Apr 2, 372(14): 1333-41.
12. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Bloodressure Control. N Engl J Med, 2015 Nov 26, 373(22): 2103-16.
13. Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. и др. «Новейшая история» лекарственной терапии больных артериальной гипертонией: только ли антигипертензивная терапия? Consilium Medicum, 2016, 18(5). / Gilyarevsky S.R., Golshmid M.V., Kuzmina I.M. et al. “The contemporary history” of drug therapy in patients with hypertension: is it only antihypertensive therapy? Consilium Medicum, 2016, 18(5).
14. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood–pressure lowering and low–dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998, 351: 1755-62.
15. Kónyi A, Sárszegi Z, Hild G, Gaszner B Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/ very high-risk patients. J Comp Eff Res, 2016 Jul, 5(4): 355-64.
16. Bertrand ME, Vlachopoulos C, Mourad JJ. Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine. Am J Cardiovasc Drugs, 2016 Aug, 16(4): 241-53.
17. Европейские клинические рекомендации по профилактике сердечно-сосудистых заболеваний (пересмотр 2012 г.). Российский кардиологический журнал, 2012, 4(96), приложение 2. / The 2012 European Guidelines on CVD Prevention in Clinical Practice. Rossiyskiy Kardiologicheskiy Zhurnal, 2012, 4(96), supplement 2.
Review
For citations:
DYAKOV IN. TREATMENT OF HYPERTENSIVE PATIENTS WITH HIGH OR VERY HIGH CARDIOVASCULAR RISK. PHARMACOECONOMIC EFFICIENCY OF A TRIPLE COMBINATION THERAPY CONTAINING ANGIOTENSIN CONVERTING ENZYME INHIBITOR, CALCIUM CHANNEL BLOCKER AND STATIN. Meditsinskiy sovet = Medical Council. 2016;(13):6-12. (In Russ.) https://doi.org/10.21518/2079-701X-2016-13-6-12
Views:
606
Email this article 